TDMS Study 55301-05 Pathology Tables
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
Facility: TSI Mason Research
Chemical CAS #: 110-86-1
Lock Date: 12/15/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 15 5 14 22
Moribund Sacrifice 3 8 7 2
Survivors
Terminal Sacrifice 32 37 29 26
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Intestine Large, Colon (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Intestine Large, Cecum (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Intestine Small, Duodenum (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Intestine Small, Ileum (50) (49) (50) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hepatocellular Adenoma 1 (2%) 1 (2%)
Mesentery (9) (11) (7) (12)
Carcinoma, Metastatic, Uterus 1 (9%)
Fibrous Histiocytoma 1 (11%)
Schwannoma Malignant, Metastatic, Uterus 1 (9%)
Oral Mucosa (2) (1) (2)
Pharyngeal, Squamous Cell Carcinoma 2 (100%)
Pharyngeal, Squamous Cell Papilloma 1 (50%)
Pancreas (49) (50) (50) (50)
Carcinoma 2 (4%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Page 2
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Acinus, Adenoma 1 (2%) 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Stomach, Glandular (50) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Tongue (1) (2)
Squamous Cell Papilloma 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Adrenal Medulla (50) (50) (50) (49)
Pheochromocytoma Benign 2 (4%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Parathyroid Gland (48) (50) (48) (50)
Pituitary Gland (49) (50) (50) (50)
Pars Distalis, Adenoma 17 (35%) 12 (24%) 18 (36%) 15 (30%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 3 (6%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (47) (48) (50) (49)
Adenoma 2 (4%) 3 (6%) 1 (2%)
Carcinoma 1 (2%) 1 (2%) 2 (4%)
Bilateral, Adenoma 1 (2%)
Ovary (50) (50) (50) (50)
Page 3
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Granulosa-Theca Tumor Malignant 1 (2%)
Uterus (50) (50) (50) (50)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Polyp Stromal 4 (8%) 7 (14%) 9 (18%) 7 (14%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Vagina (1)
Lipoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Lymph Node (7) (9) (15) (19)
Mediastinal, Carcinoma, Metastatic, Kidney 1 (11%)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (11%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (14%)
Lymph Node, Mandibular (49) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Lymph Node, Mesenteric (49) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Spleen (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Thymus (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Adenoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Fibroadenoma 19 (38%) 15 (30%) 14 (28%) 18 (36%)
Fibroadenoma, Multiple 8 (16%) 10 (20%) 6 (12%) 2 (4%)
Sarcoma 1 (2%)
Page 4
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Skin (50) (50) (50) (50)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 1 (2%)
Trichoepithelioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (1)
Carcinoma, Metastatic, Uterus 1 (100%)
Abdominal, Fibrous Histiocytoma, Metastatic,
Mesentery 1 (50%)
Abdominal, Lipoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 2 (4%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Pancreas 2 (4%)
Carcinoma, Metastatic, Uterus 1 (2%)
Nose (50) (50) (50) (50)
Pleura (1)
Carcinoma, Metastatic, Kidney 1 (100%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Mononuclear 12 (24%) 16 (32%) 22 (44%) 23 (46%)
Lymphoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 42 45 44
Total Primary Neoplasms 84 78 80 80
Total Animals with Benign Neoplasms 39 34 35 35
Total Benign Neoplasms 63 54 55 52
Total Animals with Malignant Neoplasms 21 22 23 28
Total Malignant Neoplasms 21 24 25 28
Total Animals with Metastatic Neoplasms 1 5 1 1
Total Metastatic Neoplasm 13 36 1 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 11 13 15 10
Natural Death 14 17 10 24
Survivors
Terminal Sacrifice 25 20 25 16
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (48) (50) (49)
Lipoma 1 (2%)
Intestine Large, Cecum (49) (47) (50) (49)
Lipoma 1 (2%)
Intestine Small, Duodenum (50) (47) (50) (48)
Intestine Small, Jejunum (50) (47) (50) (47)
Carcinoma 1 (2%)
Intestine Small, Ileum (50) (47) (50) (47)
Liver (50) (49) (50) (50)
Cholangiocarcinoma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 1 (2%) 1 (2%) 2 (4%)
Hepatocellular Adenoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (11) (14) (7) (8)
Schwannoma Benign 1 (9%)
Oral Mucosa (1) (2)
Pharyngeal, Squamous Cell Papilloma 1 (100%) 1 (50%)
Pancreas (50) (48) (50) (49)
Acinus, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (49) (50) (49)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (49) (50) (49)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Carcinoma 1 (2%)
Adrenal Medulla (50) (49) (50) (49)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 11 (22%) 2 (4%) 14 (28%) 4 (8%)
Bilateral, Pheochromocytoma Benign 6 (12%) 1 (2%)
Islets, Pancreatic (50) (48) (50) (49)
Adenoma 4 (8%) 2 (4%) 1 (2%)
Parathyroid Gland (50) (50) (50) (48)
Pituitary Gland (50) (50) (50) (50)
Pars Distalis, Adenoma 16 (32%) 13 (26%) 12 (24%) 11 (22%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 2 (4%) 3 (6%) 2 (4%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (49) (49) (48)
Preputial Gland (50) (47) (49) (48)
Adenoma 3 (6%) 7 (14%) 2 (4%)
Carcinoma 5 (10%) 2 (4%) 1 (2%)
Prostate (50) (48) (50) (49)
Seminal Vesicle (50) (47) (50) (48)
Testes (49) (49) (49) (48)
Bilateral, Interstitial Cell, Adenoma 33 (67%) 35 (71%) 37 (76%) 40 (83%)
Interstitial Cell, Adenoma 9 (18%) 8 (16%) 6 (12%) 3 (6%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Melanoma Malignant, Metastatic, Skin 1 (2%)
Lymph Node (20) (25) (20) (23)
Lymph Node, Mandibular (50) (50) (50) (50)
Lymph Node, Mesenteric (50) (47) (50) (48)
Spleen (49) (48) (50) (49)
Thymus (50) (49) (48) (50)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (48) (50) (49)
Carcinoma 1 (2%)
Fibroadenoma 4 (8%) 3 (6%) 6 (12%) 4 (8%)
Skin (50) (50) (50) (50)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 6 (12%) 4 (8%) 1 (2%) 5 (10%)
Keratoacanthoma, Multiple 1 (2%)
Squamous Cell Papilloma 4 (8%) 1 (2%) 1 (2%)
Trichoepithelioma 1 (2%) 1 (2%)
Pinna, Melanoma Malignant 1 (2%) 2 (4%)
Subcutaneous Tissue, Fibroma 4 (8%) 2 (4%) 4 (8%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (48) (50)
Oligodendroglioma Malignant 1 (2%)
Spinal Cord (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Page 10
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Melanoma Malignant, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Nose 1 (2%)
Nose (50) (50) (49) (50)
Osteosarcoma 1 (2%)
Respiratory Epithelium, Squamous Cell
Carcinoma 1 (2%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1) (1) (1)
Carcinoma 1 (100%) 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (48) (50) (49)
Mesenchymal Tumor Malignant 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%) 4 (8%)
Renal Tubule, Adenoma, Multiple 1 (2%) 2 (4%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (50) (47) (50) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 29 (58%) 32 (64%) 26 (52%) 27 (54%)
Lymphoma Malignant 1 (2%)
Mesothelioma Benign 1 (2%) 1 (2%)
Mesothelioma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:55:09
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 49 49 49
Total Primary Neoplasms 151 120 133 123
Total Animals with Benign Neoplasms 47 46 48 49
Total Benign Neoplasms 112 77 102 89
Total Animals with Malignant Neoplasms 34 40 29 29
Total Malignant Neoplasms 39 43 31 34
Total Animals with Metastatic Neoplasms 1 2 1
Total Metastatic Neoplasm 1 2 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------